Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers

Neuropsychobiology

Volumn 55, Issue 3-4, 2007, Pages 203-212

  Barbanoj, M J ^a,b   Urbano, G ^a   Antonijoan, R ^a   Ballester, M R ^a   Valle, M ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Alprazolam; EEG; Pharmacodynamic tolerance; Psychomotor performance; Subjective assessment

Indexed keywords

ALPRAZOLAM;

ADULT; ALPHA RHYTHM; ARTICLE; BETA RHYTHM; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; DRUG TOLERANCE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MALE; MEDICAL ASSESSMENT; NEUROPSYCHOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SAMPLE SIZE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TASK PERFORMANCE; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; ALPRAZOLAM; AREA UNDER CURVE; DRUG ADMINISTRATION ROUTES; DRUG TOLERANCE; ELECTROENCEPHALOGRAPHY; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; NEUROPSYCHOLOGICAL TESTS; PAIN MEASUREMENT; PSYCHOMOTOR PERFORMANCE; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 34948831601     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108379     Document Type: Article

References (35)

1. Linden M, Lecrubier Y, Bellantuono C, Benkert O, Kisely S, Simon G: The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. J Clin Psychopharmacol 1999;19:132-140.
2. Malizia AL, Nutt DJ: Psychopharmacology of benzodiazepines - an update. Human Psychopharmacol 1995;10:S1-S14.
3. Greenblatt DJ, Wright CE: Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet 1993;24:453-471.
4. Lapierre YD, Browne M, Oyewumi K, Sarantidis D: Alprazolam and amitriptyline in the treatment of moderate depression. Int Clin Psychopharmacol 1994;9:41-45.
5. Mohler H, Okada T: Benzodiazepine receptor: demonstration in the central nervous system. Science 1977;198:849-851.
6. Squires RF, Brastrup C: Benzodiazepine receptors in rat brain. Nature 1977;266:732-734.
7. Lerer B: In Lerer B (ed): Pharmacogenetics of Psychotropic Drugs. Cambridge, University Press, 2002.
8. Mandema JW, Kuck MT, Danhof M: In vivo modeling of the pharmacodynamic interaction between bezodiazepines which differ in intrinsic efficacy. J Pharmacol Exp Ther 1992;261:56-61.
9. Valle M, Barbanoj MJ, JanéF: Pharmaco-EEG and pharmacokinetic/ pharmacodynamic modeling in basic research: focus on human pharmacology. Methods Find Exp Clin Pharmacol 2002;24(suppl D):139-144.
10. Barbanoj MJ, Salazar G, Morte A, Antonijoan RM, Gich I, JanéF: Grounds for the integration of pharmacokinetic-pharmacodynamic data. Methods Find Exp Clin Pharmacol 1996;18(suppl C):43-45.
11. Ellinwood EH, Nikaido AM, Heatherly DG, Bjornsson TD: Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms. Psychopharmacol 1987;91:168-174.
12. Rieck W, Platt D: High-performance liquid chromatographic method for the determination of alprazolam in plasma using the column-switching technique. J Chromatogr [A] 1992;578:259-263.
13. International Pharmaco-EEG Group (IPEG): Recommendations for EEG and evoked potential mapping. Neuropsychobiology 1989;22:170-176.
14. Anderer P, Semlitsch H, Saletu B, Barbanoj MJ: Artifact processing in topographic mapping of electroctoencephalographic activity in neuropsychopharmacology. Psychiatry Res 1992;45:79-93.
15. Gibaldi M, Perrier D: In Swarbick (ed): Pharmacokinetics, ed 2. New York, Marcel Dekker, 1982.
16. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR: Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 1995;57:356-365.
17. Smith RB, Gwilt PR, Wright CE: Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin Pharm 1983;2:139-143.
18. Ciraulo DA, Barnhill JG, Boxenbaum HG, Greenblatt DJ, Smith RB: Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder. J Clin Pharmacol 1986;26:292-298.
19. Moschitto LJ, Greenblatt DJ: Concentration-independent plasma protein binding of benzodiazepines. J Pharm Pharmacol 1983;35:179-180.
20. Wright CE, Sisson TL, Fleishaker JC, Antal EJ: Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship. J Clin Pharmacol 1997;37:321-329.
21. Kroboth PD, Smith RB, Erb RJ: Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharmacol Ther 1988;43:270-277.
22. Ellinwood EH, Heatherly DG, Nikaido AM, Bjornsson TD, Kilts C: Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacol 1985;86:392-399.
23. Kroboth PD, Bertz RJ, Smith RB: Acute tolerance to triazolam during continuous and step infusions: estimation of the effect offset rate constant. J Pharmacol Exp Ther 1993;264:1047-1055.
24. Fleishaker JC, Chambers JH, Peters GR: Evaluation of the development of acute tolerance to the psychomotor effects of midazolam following intravenous infusions in healthy volunteers. Human Psychopharmacol 1995;10:97-104.
25. Bertz RJ, Kobroth PD, Kobroth FJ, Reynolds IJ, Salek F, Wright CE, Smith RB: Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor performance, sedative and memory effect. J Pharmacol Exp Ther 1997;281:1317-1329.
26. Fleishaker JC, Phillips JP, Eller MG, Smith RB: Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation. J Clin Pharmacol 1989;29:543-549.
27. Bateson AN: Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 2002;8:5-21.
28. - ion channels modulated by multiple drug-binding sites. Trends Pharmacol Sci 1992;13:446-450.
29. Kroboth PD, McAuley JW, Derry CL: Time-dependent sensitization to triazolam? An observation in three studies. J Clin Psychopharmacol 1995;15:192-196.
30. Antelman SM, Kocan D, Edwards DJ, Knopf S: Anticonvulsant and other effects of diazepam grow with time after a single treatment. Pharmacol Biochem Behav 1989;33:31-39.
31. Laurijssens BE, Greenblatt DJ: Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996;30:52-76.
32. Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI: Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther 1988;44:326-334.
33. Barbanoj MJ, Azcona O, Torrent J, Jané F: Measures and methods combining PK-PD data: Application to CNS active compounds; in Hindmarch I, Stonier PD (eds): Human Psychopharmacology. Chichester, Wiley, 1995, vol 5, pp 181-228.
34. Barbanoj MJ: Efectos sobre el S.N.C. de los ansiolíticos en el hombre. Estudios con buspirona y diacepam utilizando pruebas de rendimiento psicomotor, medidas electrofisiológicas (potenciales evocados, cartografía topográfica de la F-EEG-C) y escalas de evaluación autosubjetiva; PhD thesis, Universidad Autónoma de Barcelona, 1991.
35. Lister RG, Weingartner H, Eckardt MJ, Linnoila M: Benzodiazepine Receptor Ligands, Memory and Information Processing. Berlin, Springer, 1988.